personalize O O O O
content, O O O O
tailor O O O O
ads O O O O
and O O O O
improve O O O O
the O O O O
user O O O O
experience. O O O O
By O O O O
using O O O O
our O O O O
site, O O O O
you O O O O
agree O O O O
to O O O O
our O O O O
collection O O O O
of O O O O
information O O O O
through O O O O
the O O O O
use O O O O
of O O O O
cookies. O O O O
To O O O O
learn O O O O
more, O O O O
view O O O O
our O O O O
[Privacy O O O O
Policy.](https://www.academia.edu/privacy) O O O O
Academia.edu O O O O
no O O O O
longer O O O O
supports O O O O
Internet O O O O
Explorer. O O O O
To O O O O
browse O O O O
Academia.edu O O O O
and O O O O
the O O O O
wider O O O O
internet O O O O
faster O O O O
and O O O O
more O O O O
securely, O O O O
please O O O O
take O O O O
a O O O O
few O O O O
seconds O O O O
to O O O O
[upgrade O O O O
your O O O O
browser](https://www.academia.edu/upgrade-browser). O O O O
2011, O O O O
Pharmaceutical O O O O
Statistics O O O O
Journal O O O O
of O O O O
Clinical O O O O
Epidemiology O O O O
2009 O O O O
International O O O O
Journal O O O O
of O O O O
Environmental O O O O
Research O O O O
and O O O O
Public O O O O
Health O O O O
This O O O O
paper O O O O
presents O O O O
a O O O O
brief O O O O
overview O O O O
of O O O O
the O O O O
recent O O O O
literature O O O O
on O O O O
adaptive O O O O
design O O O O
of O O O O
clinical O O O O
trials O O O O
from O O O O
a O O O O
Bayesian O O O O
perspective O O O O
for O O O O
statistically O O O O
not O O O O
so O O O O
sophisticated O O O O
readers. O O O O
Adaptive O O O O
designs O O O O
are O O O O
attracting O O O O
a O O O O
keen O O O O
interest O O O O
in O O O O
several O O O O
disciplines, O O O O
from O O O O
a O O O O
theoretical O O O O
viewpoint O O O O
and O O O O
also—potentially—from O O O O
a O O O O
practical O O O O
one, O O O O
and O O O O
Bayesian O O O O
adaptive O O O O
designs, O O O O
in O O O O
particular, O O O O
have O O O O
raised O O O O
high O O O O
expectations O O O O
in O O O O
clinical O O O O
trials. O O O O
The O O O O
main O O O O
conceptual O O O O
tools O O O O
are O O O O
highlighted O O O O
here, O O O O
with O O O O
a O O O O
mention O O O O
of O O O O
several O O O O
trial O O O O
designs O O O O
proposed O O O O
in O O O O
the O O O O
literature O O O O
that O O O O
use O O O O
these O O O O
methods, O O O O
including O O O O
some O O O O
of O O O O
the O O O O
registered O O O O
Bayesian O O O O
adaptive O O O O
trials O O O O
to O O O O
this O O O O
date. O O O O
This O O O O
review O O O O
aims O O O O
at O O O O
complementing O O O O
the O O O O
existing O O O O
ones O O O O
on O O O O
this O O O O
topic, O O O O
pointing O O O O
at O O O O
further O O O O
interesting O O O O
reading O O O O
material. O O O O
2005 O O O O
We O O O O
explain O O O O
how O O O O
to O O O O
use O O O O
elicited O O O O
priors O O O O
in O O O O
Bayesian O O O O
political O O O O
science O O O O
research. O O O O
These O O O O
are O O O O
a O O O O
form O O O O
of O O O O
prior O O O O
information O O O O
produced O O O O
by O O O O
previous O O O O
knowledge O O O O
from O O O O
structured O O O O
interviews O O O O
with O O O O
subjective O O O O
area O O O O
experts O O O O
who O O O O
have O O O O
little O O O O
or O O O O
no O O O O
concern O O O O
for O O O O
the O O O O
statistical O O O O
aspects O O O O
of O O O O
the O O O O
project. O O O O
The O O O O
purpose O O O O
is O O O O
to O O O O
introduce O O O O
qualitative O O O O
and O O O O
area-specific O O O O
information O O O O
into O O O O
an O O O O
empirical O O O O
model O O O O
in O O O O
a O O O O
systematic O O O O
and O O O O
Haematologica O O O O
2013 O O O O
Despite Reason 4 O O
improvements Reason 4 O O
in Reason 4 O O
standard Reason 4 O O
therapy Reason 4 O O
with Reason 4 O O
rituximab, Reason 4 O O
cyclophosphamide, Reason 4 O O
doxorubicin, Reason 4 O O
vincristine Reason 4 O O
and Reason 4 O O
prednisone Reason 4 O O
for Reason 4 O O
patients Reason 4 O O
with Reason 4 O O
untreated, Reason 4 O O
diffuse Reason 4 O O
large Reason 4 O O
B-cell Reason 4 O O
lymphoma, Reason 4 O O
up Reason 4 O O
to Reason 4 O O
40% Reason 4 O O
of Reason 4 O O
these Reason 4 O O
patients Reason 4 O O
relapse. Reason 4 O O
Lenalidomide Reason 4 O O
alone Reason 4 O O
or Reason 4 O O
in Reason 4 O O
combination Reason 4 O O
with Reason 4 O O
rituximab Reason 4 O O
has Reason 4 O O
been Reason 4 O O
shown Reason 4 O O
to Reason 4 O O
be Reason 4 O O
active Reason 4 O O
in Reason 4 O O
relapsed/refractory Reason 4 O O
aggressive Reason 4 O O
lymphomas. Reason 4 O O
In Reason 4 O O
this Reason 4 O O
phase Reason 4 O O
I Reason 4 O O
study Reason 4 O O
we Reason 4 O O
determined Reason 4 O O
the Reason 4 O O
maximum Reason 4 O O
tolerated Reason 4 O O
dose Reason 4 O O
of Reason 4 O O
lenalidomide Reason 4 O O
plus Reason 4 O O
rituximab, Reason 4 O O
cyclophosphamide, Reason 4 O O
doxorubicin, Reason 4 O O
vincristine Reason 4 O O
and Reason 4 O O
prednisone Reason 4 O O
in Reason 4 O O
untreated, Reason 4 O O
elderly Reason 4 O O
(median Reason 4 O O
age Reason 4 O O
68 Reason 4 O O
years) Reason 4 O O
patients Reason 4 O O
with Reason 4 O O
diffuse Reason 4 O O
large Reason 4 O O
B-cell Reason 4 O O
lymphoma. Reason 4 O O
Four Reason 4 O O
lenalidomide Reason 4 O O
doses Reason 4 O O
(5, Reason 4 O O
10, Reason 4 O O
15, Reason 4 O O
and Reason 4 O O
20 Reason 4 O O
mg/day Reason 4 O O
on Reason 4 O O
days Reason 4 O O
1-14) Reason 4 O O
allocated Reason 4 O O
using Reason 4 O O
the Reason 4 O O
continual Reason 4 O O
reassessment Reason 4 O O
method Reason 4 O O
were Reason 4 O O
planned Reason 4 O O
to Reason 4 O O
be Reason 4 O O
administered Reason 4 O O
for Reason 4 O O
14 Reason 4 O O
days Reason 4 O O
in Reason 4 O O
combination Reason 4 O O
with Reason 4 O O
each Reason 4 O O
course Reason 4 O O
of Reason 4 O O
rituximab, Reason 4 O O
cyclophosphamide, Reason 4 O O
doxorubicin, Reason 4 O O
vincristine Reason 4 O O
and Reason 4 O O
prednisone Reason 4 O O
for Reason 4 O O
a Reason 4 O O
total Reason 4 O O
of Reason 4 O O
six Reason 4 O O
courses. Reason 4 O O
Seven Reason 4 O O
cohorts Reason 4 O O
of Reason 4 O O
patients Reason 4 O O
(n=3 Reason 4 O O
in Reason 4 O O
each Reason 4 O O
cohort) Reason 4 O O
were Reason 4 O O
treated Reason 4 O O
(total Reason 4 O O
n=21) Reason 4 O O
at Reason 4 O O
10, Reason 4 O O
20, Reason 4 O O
15, Reason 4 O O
15, Reason 4 O O
15, Reason 4 O O
10, Reason 4 O O
and Reason 4 O O
10 Reason 4 O O
mg Reason 4 O O
of Reason 4 O O
lenalidomide. Reason 4 O O
D... Reason 4 O O
Therapeutic Reason 4 O O
Innovation Reason 4 O O
and Reason 4 O O
Regulatory Reason 4 O O
Science Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
the Reason 4 O O
American Reason 4 O O
Statistical Reason 4 O O
Association Reason 4 O O
2005 Reason 4 O O
Blood Reason 4 O O
2013 Reason 4 O O
Key Reason 4 O O
Points Reason 4 O O
Pomalidomide-cyclophosphamide-prednisone Reason 4 O O
is Reason 4 O O
an Reason 4 O O
active Reason 4 O O
combination Reason 4 O O
in Reason 4 O O
multiple Reason 4 O O
myeloma Reason 4 O O
patients Reason 4 O O
who Reason 4 O O
are Reason 4 O O
relapsed/refractory Reason 4 O O
to Reason 4 O O
lenalidomide. Reason 4 O O
Real Reason 4 O O
Estate Reason 4 O O
Economics Reason 4 O O
2006 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Business Reason 4 O O
& Reason 4 O O
Economic Reason 4 O O
Statistics Reason 4 O O
2010 Reason 4 O O
The Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
the Reason 4 O O
Operational Reason 4 O O
Research Reason 4 O O
Society Reason 4 O O
2009 Reason 4 O O
Loading Reason 4 O O
Preview Reason 4 O O
Sorry, Reason 4 O O
preview Reason 4 O O
is Reason 4 O O
currently Reason 4 O O
unavailable. Reason 4 O O
You Reason 4 O O
can Reason 4 O O
download Reason 4 O O
the Reason 4 O O
paper Reason 4 O O
by Reason 4 O O
clicking Reason 4 O O
the Reason 4 O O
button Reason 4 O O
above. Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Statistical Reason 4 O O
Planning Reason 4 O O
and Reason 4 O O
Inference Reason 4 O O
2010 Reason 4 O O
Chemometrics Reason 4 O O
and Reason 4 O O
Intelligent Reason 4 O O
Laboratory Reason 4 O O
Systems Reason 4 O O
1996 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Applied Reason 4 O O
Econometrics Reason 4 O O
2011 Reason 4 O O
2013 Reason 4 O O
2007 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Evaluation Reason 4 O O
in Reason 4 O O
Clinical Reason 4 O O
Practice Reason 4 O O
2010 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Statistical Reason 4 O O
Research Reason 4 O O
2022 Reason 4 O O
BMC Reason 4 O O
Medical Reason 4 O O
Research Reason 4 O O
Methodology Reason 4 O O
2016 Reason 4 O O
Communications Reason 4 O O
in Reason 4 O O
Statistics Reason 4 O O
Theory Reason 4 O O
and Reason 4 O O
Methods Reason 4 O O
1995 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Evaluation Reason 4 O O
in Reason 4 O O
Clinical Reason 4 O O
Practice Reason 4 O O
2010 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Evaluation Reason 4 O O
in Reason 4 O O
Clinical Reason 4 O O
Practice Reason 4 O O
2010 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Statistical Reason 4 O O
Planning Reason 4 O O
and Reason 4 O O
Inference Reason 4 O O
2008 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Clinical Reason 4 O O
Epidemiology Reason 4 O O
2008 Reason 4 O O
BMC Reason 4 O O
Medical Reason 4 O O
Research Reason 4 O O
Methodology Reason 4 O O
Conservation Reason 4 O O
... Reason 4 O O
2011 Reason 4 O O
Controlled Reason 4 O O
Clinical Reason 4 O O
Trials Reason 4 O O
2003 Reason 4 O O
BMC Reason 4 O O
Medicine Reason 4 O O
Environmetrics Reason 4 O O
2009 Reason 4 O O
... Reason 4 O O
2009 Reason 4 O O
2007 Reason 4 O O
Annual Reason 4 O O
Review Reason 4 O O
of Reason 4 O O
Public Reason 4 O O
Health Reason 4 O O
1995 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
advanced Reason 4 O O
nursing Reason 4 O O
2011 Reason 4 O O
2006 Reason 4 O O
Thailand Reason 4 O O
Statistician Reason 4 O O
2015 Reason 4 O O
2013 Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Behavioral Reason 4 O O
Decision Reason 4 O O
Making Reason 4 O O
1991 Reason 4 O O
British Reason 4 O O
journal Reason 4 O O
of Reason 4 O O
cancer Reason 4 O O
2017 Reason 4 O O
2009 Reason 4 O O
Ophthalmic Reason 4 O O
epidemiology Reason 4 O O
2016 Reason 4 O O
Ecological Reason 4 O O
Applications Reason 4 O O
1996 Reason 4 O O
Value Reason 4 O O
in Reason 4 O O
Health Reason 4 O O
2010 Reason 4 O O
International Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Technology Reason 4 O O
Assessment Reason 4 O O
in Reason 4 O O
Health Reason 4 O O
Care Reason 4 O O
2008 Reason 4 O O
Statistics Reason 4 O O
in Reason 4 O O
Medicine Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Reliability Reason 4 O O
and Reason 4 O O
Statistical Reason 4 O O
Studies Reason 4 O O
2011 Reason 4 O O
